MX2024011183A - Tratamientos conjuntos para el cancer de mama. - Google Patents

Tratamientos conjuntos para el cancer de mama.

Info

Publication number
MX2024011183A
MX2024011183A MX2024011183A MX2024011183A MX2024011183A MX 2024011183 A MX2024011183 A MX 2024011183A MX 2024011183 A MX2024011183 A MX 2024011183A MX 2024011183 A MX2024011183 A MX 2024011183A MX 2024011183 A MX2024011183 A MX 2024011183A
Authority
MX
Mexico
Prior art keywords
breast cancer
combination therapies
trastuzumab
pertuzumab
positive
Prior art date
Application number
MX2024011183A
Other languages
English (en)
Spanish (es)
Inventor
Jing Zhu
Eleonora Restuccia
Daniel Eiger
Marc Antoine Hafner
Sarah Louise Heeson
Ciara Metcalfe
Mina Nikanjam
Raf Poppe
Mahesh Ratanlal Shivhare
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2024011183A publication Critical patent/MX2024011183A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2024011183A 2022-03-14 2023-03-10 Tratamientos conjuntos para el cancer de mama. MX2024011183A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263269326P 2022-03-14 2022-03-14
PCT/US2023/064143 WO2023178019A1 (en) 2022-03-14 2023-03-10 Combination therapies for breast cancer

Publications (1)

Publication Number Publication Date
MX2024011183A true MX2024011183A (es) 2024-09-18

Family

ID=85937455

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011183A MX2024011183A (es) 2022-03-14 2023-03-10 Tratamientos conjuntos para el cancer de mama.

Country Status (11)

Country Link
US (1) US20250177364A1 (cg-RX-API-DMAC7.html)
EP (1) EP4493180A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025509510A (cg-RX-API-DMAC7.html)
KR (1) KR20240163084A (cg-RX-API-DMAC7.html)
CN (1) CN118843461A (cg-RX-API-DMAC7.html)
AU (1) AU2023234511A1 (cg-RX-API-DMAC7.html)
CA (1) CA3254271A1 (cg-RX-API-DMAC7.html)
IL (1) IL315153A (cg-RX-API-DMAC7.html)
MX (1) MX2024011183A (cg-RX-API-DMAC7.html)
TW (1) TW202400230A (cg-RX-API-DMAC7.html)
WO (1) WO2023178019A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至her2結構域ii之抗體及其酸性變異體的組合物
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック, インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2437300A (en) 1999-01-15 2000-08-01 Infineum International Ltd Improved fuel compositions
DK3570884T3 (da) 2017-01-17 2020-11-30 Genentech Inc Subkutane HER2-antistofformuleringer
KR20230009390A (ko) * 2020-05-12 2023-01-17 제넨테크, 인크. Gdc-9545 및 cdk4/6 억제제를 포함하는 병용 요법을 사용한 유방암 치료
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック, インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤
AU2021308283A1 (en) 2020-07-14 2023-02-02 F. Hoffmann-La Roche Ag Assays for fixed dose combinations

Also Published As

Publication number Publication date
JP2025509510A (ja) 2025-04-11
KR20240163084A (ko) 2024-11-18
IL315153A (en) 2024-10-01
CN118843461A (zh) 2024-10-25
EP4493180A1 (en) 2025-01-22
AU2023234511A1 (en) 2024-09-12
WO2023178019A1 (en) 2023-09-21
CA3254271A1 (en) 2023-09-21
TW202400230A (zh) 2024-01-01
US20250177364A1 (en) 2025-06-05

Similar Documents

Publication Publication Date Title
Tupchong et al. Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03
MX2025001714A (es) Medicamento para el tratamiento y/o prevencion del cancer
Martinez et al. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime
Wang-Chesebro et al. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer
Hoskin et al. High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: acute toxicity
IL315153A (en) Combined treatments for breast cancer
MX2021007350A (es) Terapia combinada de cd70 y venetoclax, un inhibidor de bcl-2, para tratar la leucemia mieloide aguda.
MX2023006793A (es) Tratamientos conjuntos para tratamiento de cancer her2.
UA94899C2 (ru) Фиксированное дозирование антител к her
MX2023002805A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos.
ATE425749T1 (de) Behandlung von mit her-2/neu-uberexprimierung einhergehendem krebs
CA3242265A1 (en) Use of combination therapy for treating cancer
Marina et al. Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients
MX2025002839A (es) Combinacion farmaceutica y uso de la misma
Yazar et al. Oncoplastic breast conserving surgery: aesthetic satisfaction and oncological outcomes
AU2021334165A8 (en) Method of treatment of patients having reduced sensitivity to a BCL-2 inhibitor
Teo et al. Improved local control for early T-stage nasopharyngeal carcinoma–a tale of two hospitals
Hayakawa et al. The Effect of Overall Treatment Time of Radiation Therapy on Local Control of T1‐Stage Squamous Call Carcinoma of the Glottis
EP4706653A3 (en) Therapeutic compositions comprising idelalisib and defactinib for treating breast cancers
Tang et al. Outcomes after PD-103 versus I-125 for low dose rate prostate brachytherapy monotherapy: An international, multi-institutional study
Jensen et al. Dose escalated simultaneous integrated boost of gross nodal disease in gynecologic cancers: a multi-institutional retrospective analysis and review of the literature
MX2025002182A (es) Terapias de combinacion que usan inhibidores de proteina arginina n-metil transferasa 5 (prmt5) e inhibidores de la familia del oncogen de linfoma de celulas b 2 (bcl-2) para el tratamiento del cancer
Owari et al. Impact of neoadjuvant androgen deprivation therapy on postimplant prostate D90 and prostate volume after low‐dose‐rate brachytherapy for localized prostate cancer
Guttmann et al. Comparison of acute toxicities between contemporary forward‐planned 3D conformal radiotherapy and inverse‐planned intensity‐modulated radiotherapy for whole breast radiation
Nagar et al. CT vs. MRI for image-guided brachytherapy in locally advanced cervical cancer: A Propensity Score Matched Analysis